[1] Blanco N, Harris AD, Rock C, et al. Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission. Antimicrob Agents Chemother 2018;62(1).
[2] Busani S, Serafini G, Mantovani E, et al. Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria: Risk Factors and Impact of Sepsis Treatments. J Intensive Care Med 2019;34(1):48–54.
[3] Sheng W-H, Liao C-H, Lauderdale T-L, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010;14(9):e764-769.
[4] Tomczyk S, Zanichelli V, Grayson ML, et al. Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies. Clin Infect Dis 2019;68(5):873–84.
[5] ECDC. ECDC country visit to Italy to discuss antimicrobial resistance issues [Internet]. 2017;Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AMR-country-visit-Italy.pdf.
[6] Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist 2018;11:1249–60.
[7] Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care 2018;24(5):385–93.
[8] Zollner-Schwetz I, Zechner E, Ullrich E, et al. Colonization of long term care facility patients with MDR-Gram-negatives during an Acinetobacter baumannii outbreak. Antimicrob Resist Infect Control [Internet] 2017 [cited 2020 Feb 12];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434526.
[9] Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358(12):1271–81.
[10] Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control. Infection Control & Hospital Epidemiology 2017;38(5):580–94.
[11] Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16(2):102–11.
[12] Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control 2016;44(5):e65-71.
[13] Rodríguez-Baño J, Martí S, Soto S, et al. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect 2008;14(3):276–8.
[14] Corbella X, Pujol M, Ayats J, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis 1996;23(2):329–34.
[15] Latibeaudiere R, Rosa R, Laowansiri P, Arheart K, Namias N, Munoz-Price LS. Surveillance cultures growing carbapenem-Resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin Infect Dis 2015;60(3):415–22.
[16] Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65(3):204–11.
[17] Mody L, Gibson KE, Horcher A, et al. Prevalence of and risk factors for multidrug-resistant Acinetobacter baumannii colonization among high-risk nursing home residents. Infect Control Hosp Epidemiol 2015;36(10):1155–62.
[18] Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii. Antimicrob Resist Infect Control 2015;4:40.
[19] Henig O, Weber G, Hoshen MB, et al. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study. Eur J Clin Microbiol Infect Dis 2015;34(10):2063–8.
[20] Kiddee A, Assawatheptawee K, Na-Udom A, et al. Risk Factors for Gastrointestinal Colonization and Acquisition of Carbapenem-Resistant Gram-Negative Bacteria among Patients in Intensive Care Units in Thailand. Antimicrob Agents Chemother 2018;62(8).
[21] Moghnieh R, Siblani L, Ghadban D, et al. Extensively drug-resistant Acinetobacter baumannii in a Lebanese intensive care unit: risk factors for acquisition and determination of a colonization score. J Hosp Infect 2016;92(1):47–53.
[22] Nucleo E, Caltagirone M, Marchetti VM, et al. Colonization of long-term care facility residents in three Italian Provinces by multidrug-resistant bacteria. Antimicrob Resist Infect Control [Internet] 2018 [cited 2020 Feb 12];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839059.
[23] Martín-Aspas A, Guerrero-Sánchez FM, García-Colchero F, Rodríguez-Roca S, Girón-González J-A. Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infect Drug Resist 2018;11:861–72.
[24] Thuy DB, Campbell J, Nhat LTH, et al. Hospital-acquired colonization and infections in a Vietnamese intensive care unit. PLoS ONE 2018;13(9):e0203600.
[25] Charlson M, Szatrowski TP, Peterson J, Gold J. J Clin Epidemiol Vol. 47, No. 11, pp. 1245-1251, 1994.
[26] Reilly J, Coignard B, Price L, et al. The reliability of the McCabe score as a marker of co-morbidity in healthcare-associated infection point prevalence studies. J Infect Prev 2016;17(3):127–9.
[27] Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 2008;62(5):1130–7.